Sutro Biopharma (STRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sutro Biopharma (STRO) has a cash flow conversion efficiency ratio of 0.371x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.29 Million) by net assets ($-103.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see STRO market cap for the company's overall valuation and market capitalisation.
Sutro Biopharma - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Sutro Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sutro Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sutro Biopharma ranked by their cash flow conversion efficiency. Explore STRO operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metalfrio Solutions S.A
SA:FRIO3
|
0.428x |
|
Richmond Mutual Bancorporation Inc
NASDAQ:RMBI
|
0.020x |
|
Wam Microcap Ltd
AU:WMI
|
0.033x |
|
Youlchon Chem
KO:008730
|
0.029x |
|
Gaon Group Ltd
TA:GAGR
|
0.123x |
|
Jackson Acquisition Company II
NYSE:JACS
|
-0.001x |
|
Aldel Financial II Inc. Class A Ordinary Shares
NASDAQ:ALDF
|
0.010x |
|
Burgenland Holding Aktiengesellschaft
VI:BHD
|
N/A |
Annual Cash Flow Conversion Efficiency for Sutro Biopharma (2016–2025)
The table below shows the annual cash flow conversion efficiency of Sutro Biopharma from 2016 to 2025. View Sutro Biopharma (STRO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-132.45 Million | $-177.23 Million | 1.338x | +131.16% |
| 2024-12-31 | $44.60 Million | $-191.54 Million | -4.295x | -475.79% |
| 2023-12-31 | $149.65 Million | $-111.62 Million | -0.746x | -4661.44% |
| 2022-12-31 | $217.05 Million | $3.55 Million | 0.016x | +105.06% |
| 2021-12-31 | $252.56 Million | $-81.68 Million | -0.323x | -58.38% |
| 2020-12-31 | $332.05 Million | $-67.80 Million | -0.204x | +69.29% |
| 2019-12-31 | $97.79 Million | $-65.02 Million | -0.665x | -789.62% |
| 2018-12-31 | $131.54 Million | $12.68 Million | 0.096x | -71.65% |
| 2017-12-31 | $-109.00 Million | $-37.07 Million | 0.340x | +135.06% |
| 2016-12-31 | $-90.90 Million | $-13.15 Million | 0.145x | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid… Read more